Search

Tirzepatide is a dual GIP and GLP-1 receptor agonist approved by the FDA (as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). It is supported by large phase 3 randomized controlled trials demonstrating significant glycemic and weight outcomes. It is a prescription medication; non-prescription research-chemical sourcing carries substantial purity and safety risks.